In HERNATA study, TTP (15.3 months vs. 12.4 months; HR: 094), OS (35.7 months vs. 38.8 months; HR: 1.01) was analogous to the study assessing trastuzumab+vinorelbine compared with trastuzumab+docetaxel as the primary treatment of HER2-positive advanced and recurrent breast cancer [23]. Here, ERBB2 is linked to breast carcinoma.